Read More

Mesoblast Announced Single Intervention With Rexlemestrocel-l Improves Left Ventricular Ejection Fraction at 12 Months, Preceding Long-term Reduction in Major Adverse Cardiovascular Events

Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that treatment of HFrEF patients with rexlemestrocel-L, its allogeneic "off-the-shelf" product candidate for the treatment of chronic heart failure with reduced ejection fraction, resulted in greater improvement in the pre-specified analysis of left ventricular ejecti

MESO

Read More

TotalEnergies and ADNOC Expand Strategic Alliance

On the occasion of the state visit in Paris of His Highness Sheikh, Mohamed bin Zayed Al Nahyan, President of the United Arab Emirates, TotalEnergies (Paris:TTE) (LSE:TTE) (NYSE: TTE) and Abu Dhabi National Oil Company (ADNOC) have signed a strategic partnership agreement that aims to jointly evaluate new growth opportunities in

PARIS:TTE

Read More

AstraZeneca Announced Enhertu Approved in the EU for Patients With HER2-Positive Metastatic Breast Cancer Treated With One or More Prior Anti-HER2-based Regimens

Approval broadens indication for AstraZeneca and Daiichi Sankyo's Enhertu across Europe to earlier use in HER2-positive metastatic breast cancer. Based on ground-breaking DESTINY-Breast03 results in which Enhertu demonstrated a 72% reduction in the risk of disease progression or death vs. trastuzumab emtansine (T-DM1).

AZN

Read More

Groupe Beneteau Launched Partnership With Vision Marine Technologies to Develop and Market 100% Electric Outboard-equipped Powerboats

Groupe Beneteau, a global market leader in recreational boating, and Vision Marine Technologies, the leader in electric transition of the recreational boating industry, have launched a partnership to integrate Vision Marine Technologies revolutionary, high-power outboard motors onboard several models across Groupe Beneteau's brand portfolio.

VMAR